FINWIRES · TerminalLIVE
FINWIRES

Guggenheim Initiates First Tracks Biotherapeutics at Buy

By

First Tracks Biotherapeutics (TRAX) has an average rating of buy and mean price target of $72.50, according to analysts polled by FactSet.

What else is happening in Research?